Select Language
HLA-A*0201 & B2M & WT-1
Product Inquiry
HLA-A*0201 & B2M & WT-1 Background
Wilms tumor gene 1 (WT1), is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Rocatinlimab | KHK-4083; AMG-451 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd, Amgen Inc | Abdominal Pain; Inflammatory Bowel Diseases; Digestive System Diseases; Gastrointestinal Diseases; Autoimmune Diseases; Colitis; Asthma; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases | Details |
| Ivuxolimab | PF-8600; PF-04518600 | Phase 3 Clinical | Pfizer Inc | Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| INBRX-106 | INBRX-106; ES-102; ES102 | Phase 3 Clinical | Inhibrx | Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| GSK3174998 | GSK3174998; GSK 3174998; GSK-3174998 | Phase 2 Clinical | Glaxosmithkline Plc | Neoplasms; Multiple Myeloma | Details |
| Telazorlimab | GBR-830; ISB-830 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Dermatitis, Atopic | Details |
| BMS-986178 | BMS-986178 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| SAR-442970 | SAR-442970 | Phase 2 Clinical | Sanofi | Inflammation; Hidradenitis Suppurativa | Details |
| IMG-007 | IMG-007 | Phase 2 Clinical | Alopecia Areata; Dermatitis, Atopic | Details | |
| BAT-6026 | BAT-6026 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd, Bio-Thera Solutions Ltd | Solid tumours; Autoimmune Diseases; Dermatitis, Atopic | Details |
| BGB-A445 | BGB-A445 | Phase 2 Clinical | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details | |
| Recombinant human anti-OX40 monoclonal antibody (Livzon Group) | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Neoplasms | Details | |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc | Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma | Details |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasms; Neoplasm Metastasis | Details |
| Cudarolimab | IBI-101 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| Revdofilimab | ABBV-368; PR-1628103 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SHR-1806 | SHR-1806 | Phase 1 Clinical | Neoplasms | Details | |
| Tavolimab | MEDI-0562 | Phase 1 Clinical | Medimmune | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma | Details |
| Vonlerolizumab | RG-7888; MOXR-0916; RO-7021608 | Phase 1 Clinical | Genentech Inc | Neoplasms; Carcinoma, Transitional Cell | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) | YH-002 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours | Details |
| HFB-3010(HiFiBiO Therapeutics) | HFB-3010; HFB-301001 | Phase 1 Clinical | HiFiBiO Therapeutics | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| HLX-51 | HLX-51 | Phase 1 Clinical | Solid tumours; Lymphoma | Details | |
| KN-052 | KN-052 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Solid tumours | Details |
| MEDI-6469 | MEDI-6469; AGX-051 | Phase 1 Clinical | Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services | Liver Neoplasms; Head and Neck Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis | Details |
- Product Inquiry
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main